

REMARKS

Amendments to the Specification

Page 1 of the specification is amended to identify applications to which priority is claimed.

Discussion of New Claims

Original claims 1-37 are canceled. New claims 38-46 are added. Support for the new claims 38-46 is found in the application as originally filed, including at page 6, lines 6-13, wherein it is described that use of an agent capable of neutralizing or down regulating immunosuppressive factors results in synergistic enhancement of cytotoxic T lymphocyte response induced by a vaccine; at page 4, lines 2-6, wherein use of agents capable of neutralizing, antagonizing, down regulating, or blocking TGF β activity is described; at page 7, line 14, where TGF β is identified as a potent immunosuppressant; at page 4, lines 20-24, and at page 9, line 8, through page 10, line 2, wherein various TGF β antagonists are described, including anti-TGF β antibodies, TGF β receptor Fc-fusion proteins, TGF β analogs, and TGF β binding polypeptides such as thrombospondin peptide; at page 15, lines 10-13, wherein it is described that the disclosed methods are useful for treatment of diseases and conditions in which TGF β has an adverse effect on the host's ability to elicit a therapeutic CTL response, such as cancers, neoplastic growths, viral infections, and parasitic infections, at page 13, line 3, through page 14, line 21, wherein various disease-related and infection-related antigens are identified; and at page 4, lines 8-20, wherein it a CTL-inducing composition for use in conjunction with an antagonist of an immunosuppressive factor is described. No new matter is added. Entry of new claims 37-45 is respectfully requested.

Conclusion

If any questions arise regarding the foregoing amendments, which the examiner feels may be best resolved through a personal or telephone interview, he is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,
PILLSBURY WINTHROP LLP


Thomas A. Cawley, Jr., Ph.D.
Registration No. 40,944

P.O. Box 10500
McLean, VA 22102
(703) 905-2144 Direct Dial
(703) 905-2500 Facsimile

Date: December 24, 2003

TAC/JBM